National Vision Stock Down Despite Q2 Earnings & Revenue Beat

Following the earnings announcement, EYE shares lost 7.9% yesterday. 

EYE's Store Trends Show Mixed Brand Performance

Comparable store sales increased 3.4% in the quarter. Revenues also benefited from a positive 0.8% impact tied to the timing of unearned revenues, while lower self-pay customer traffic partly offset gains from ticket and managed care.

America’s Best comparable sales rose 2.5%, while Eyeglass World’s increased 0.4%. Military comparable sales declined 2.9%, while Fred Meyer’s fell 7.4%. EYE opened nine America's Best stores and closed two, ending the quarter with 1,281 stores, up 3.3% overall.

EYE’s Margin

On a consolidated basis, gross profit in the second quarter increased 1.5% year over year to $290.4 million, supported by higher revenues of $498.8 million. Gross margin was 58.2%, down roughly 58 bps from the prior-year quarter’s level, as costs applicable to revenues rose 4.0% to $208.4 million.

SG&A expenses declined 1.5% year over year to $243.4 million. Operating income climbed 29.5% to $21.3 million, translating into an operating margin of 4.3%, which expanded roughly 89 bps year over year.

National Vision's Liquidity Supports Capital Flexibility

National Vision ended the quarter with $36.0 million in cash. Total debt was $237.7 million, while no borrowings were outstanding under its $300 million first-lien revolving credit facility, excluding $6.7 million of letters of credit.

During the quarter, the company repurchased about 1.2 million shares for $20.0 million, leaving $30.0 million under its authorization. For the first six months of 2026, net cash provided by operating activities was $69.8 million versus $86.5 million a year earlier. Purchases of property and equipment totaled $39.8 million compared with $32.1 million in the prior-year period.

EYE Raises Its 2026 Profit Outlook

EYE narrowed its adjusted comparable store sales growth outlook to 3.0-5.0% from 3.0-6.0%. Net revenues are now projected to be $2.037-$2.076 billion (previously $2.033-$2.091 billion). The Zacks Consensus Estimate for the metric is currently pegged at $2.06 billion.

The company also lifted the lower end of its adjusted diluted earnings guidance of $0.94-$1.09 (previously $0.85-$1.09). The Zacks Consensus Estimate is currently pegged at 94 cents.

Our Take on National Vision 

National Vision ended the second quarter of 2026 with better-than-expected earnings and revenues. Also, operating margin expansion looks promising. 

The company remained disciplined in pursuing growth, with an intentional shift toward a healthier customer base, improved product mix and a better customer experience. It also completed its website replatform, moving to a unified commerce foundation designed to connect the exam, prescription and retail journey at scale. 

Additionally, EYE’s gross margin contraction looks discouraging. 

EYE’s Zacks Rank and Key Picks 

National Vision currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks from the broader medical space are Intuitive Surgical ISRG, Quest Diagnostics DGX and Medpace MEDP.

Intuitive Surgical, carrying a Zacks Rank #2 (Buy) at present, reported second-quarter 2026 adjusted EPS of $2.80, which surpassed the Zacks Consensus Estimate by 12.9%. Revenues of $2.89 billion beat the Zacks Consensus Estimate by 3.1%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

ISRG has an earnings yield of 3.1% compared to the industry’s negative 3% yield. The company beat earnings estimates in each of the trailing four quarters, the average surprise being 16.53%.

Quest Diagnostics, carrying a Zacks Rank #2 at present, posted second-quarter 2026 adjusted EPS of $3.12, which outpaced the Zacks Consensus Estimate by 11%. Revenues of $3.04 billion topped the Zacks Consensus Estimate by 2.1%.

DGX has an earnings yield of 4.7%, almost in line with the industry’s yield. The company’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 5.77%.

Medpace, carrying a Zacks Rank #2 at present, posted second-quarter 2026 adjusted EPS of $4.25, which beat the Zacks Consensus Estimate by 4.17%. Revenues of $707.3 million outperformed the consensus mark by 1.12%.

MEDP has a historical five-year earnings growth rate of 30.5% compared with the industry’s 5.6% growth. In the trailing four quarters, the company delivered an average earnings beat of 10.16%.

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research